Democratic control of Congress reshapes the health committees. STAT reported that Senators Wyden and Sanders, both backers of Medicare for All, are set to take charge of key Senate health committees, and that Senator Sanders is positioned to hold major sway over the FDA funding bill and the PDUFA reauthorisation. STAT’s wider midterm takeaways, and a separate analysis arguing Democrats have won power to push back on the administration’s health care moves, make the same point from different angles: drug pricing and agency oversight hearings are the likely first uses of that power, not legislation that can survive a veto. Analysts cited by BioPharma Dive expected biopharma shares to climb after the result.
The first wave of abstracts for the American Society of Hematology annual meeting, December 12 to 15 in New Orleans, was released, with data flagged from Johnson and Johnson, Servier and AstraZeneca, Endpoints News reported. The Kamau sickle cell data in today’s edition is part of the same abstract release. Abstract level data are preliminary and frequently change by the meeting, and no individual ASH result beyond Kamau’s is claimed here.
Summit Therapeutics faces the sector’s nearest binary date. Its application for ivonescimab plus chemotherapy in EGFR mutated non-squamous lung cancer after a third generation EGFR inhibitor has a company reported FDA goal action date of November 14, 2026, and the company plans a conference call after the agency acts. Summit’s filings in the pool for this run were routine, a prospectus supplement and a legal opinion (accession 0001193125-26-447661) plus a shareholder vote to double authorised shares, and are not news in themselves. The substance is the decision: the Phase 3 HARMONi trial met its progression free survival endpoint, and the company has disclosed that the FDA considers statistically significant overall survival necessary in this setting, which the original analysis did not reach.
The UK MHRA published guidance on its assessment of non-clinical data generated outside the OECD mutual acceptance system, and on using such data in support of UK clinical trial authorisations. It is a technical regulatory clarification with no immediate market effect, noted here so the change of position is on the record.